Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer.
- Author:
Wang-jun LIAO
1
;
Peng SHEN
;
Wen yun WU
;
Min SHI
;
Rong-cheng LUO
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Camptothecin; administration & dosage; adverse effects; analogs & derivatives; Capecitabine; Colorectal Neoplasms; drug therapy; secondary; Deoxycytidine; administration & dosage; adverse effects; analogs & derivatives; Endostatins; administration & dosage; adverse effects; genetics; Female; Fluorouracil; administration & dosage; adverse effects; analogs & derivatives; Humans; Male; Middle Aged; Recombinant Proteins; administration & dosage; adverse effects
- From: Journal of Southern Medical University 2010;30(4):813-814
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the short-term efficacy and toxicity of endostar in combination with XELIRI as the second-line treatment for advanced colorectal cancer.
METHODSTwenty-one patients with advanced colorectal cancer were treated with intravenous infusion of endostar (15 mg/day for 14 consecutive days) and irinotecan (250 mg/m(2), single dose on the first day), and oral administration of capecitabine (1.0 mg/m(2), twice daily for 14 days), and the treatment cycle was repeated every 21 days. The efficacy and toxicity of the treatments were evaluated according to RECIST and NCI-CTCAE3.0 standard, respectively.
RESULTSThe overall response rate was 9.5% in these patients, with a median time to progression (mTTP) of 3.9 months. The main adverse effects associated with the treatment included leucopenia, nausea/vomiting and peripheral neuritis.
CONCLUSIONEndostar combined with XELIRI is effective and safe as the second-line treatment for advanced colorectal cancer, and further clinical investigation is warranted.
